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The purpose of this study was to determine the intracellular trafﬁcking and release pathways for the
therapeutic protein, viral IL-10 (vIL-10), from transduced acinar epithelial cells from rabbit lacrimal
gland. Primary cultured rabbit lacrimal gland acinar cells (LGACs) were transduced with adenovirus
serotype 5 containing viral interleukin-10 (AdvIL-10). The distribution of vIL-10 was assessed by confocal
ﬂuorescence microscopy. Carbachol (CCH)-stimulated release of vIL-10 was quantiﬁed by ELISA. vIL-10
localization and exocytosis was probed in response to treatments with agents modulating actin- and
myosin-based transport. vIL-10 immunoreactivity was detected in large intracellular vesicles in trans-
duced LGAC. vIL-10 was partially co-localized with biosynthetic but not endosomal compartment
markers. vIL-10 release was sensitive to CCH, and the kinetics of release showed an initial burst phase
that was similar but not identical to that of the secretory protein, b-hexosaminidase. Disassembly of actin
ﬁlaments with latrunculin B signiﬁcantly increased CCH-stimulated vIL-10 secretion, suggesting that vIL-
10 was released from stores sequestered beneath the subapical actin barrier. That release required the
activity of actin-dependent myosin motors previously implicated in secretory vesicle exocytosis was
conﬁrmed by ﬁndings that CCH-stimulated vIL-10 release was reduced by inhibition of non-muscle
myosin 2 and myosin 5c function, using ML-7 and overexpression of dominant negative myosin 5c,
respectively. These results suggest that the majority of vIL-10 transgene product is packaged into
a subpopulation of secretory vesicles that utilize actin-dependent myosin motors for aspects of actin coat
assembly, compound fusion and exocytosis at the apical plasma membrane in response to CCH
stimulation.
 2008 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
A common cause of ocular morbidity in developed countries is
keratoconjunctivitis sicca (KCS) or ‘‘dry eye’’. KCS due to lacrimal
insufﬁciency is termed tear-deﬁcient KCS, and this form of KCS
affects tens of millions of people around the world (Schaumberg, Sjo¨gren’s syndrome; vIL-10,
ruitable secretory vesicle(s);
d5, adenovirus serotype 5;
leukin-10; Myo5c, myosin 5c;
ontaining green ﬂuorescent
ontaining the GFP-fused tail
endosomal antigen 1; MOI,
buffered saline.
ye Institute, USC Keck School
eles, CA 90033, USA. Tel.: þ1
usdale).
Y-NC-ND license.et al., 2003). Tear-deﬁcient KCS can be a consequence of the auto-
immune disease, Sjo¨gren’s syndrome (SjS), affecting 1–5 million
Americans each year, or occur through SjS-independent mecha-
nisms (Mircheff et al., 2005; Lemp, 2005; Zoukhri, 2006). SjS is
characterized by lymphocytic inﬁltration of the lacrimal and sali-
vary glands. These cellular inﬁltrates produce pro-inﬂammatory
cytokines that cause severe functional impairment of the glands
leading to dry eyes (i.e. KCS) and dry mouth (i.e. xerostomia)
(Mircheff et al., 2005; Lemp, 2005; Zoukhri, 2006). SjS and other
forms of tear-deﬁcient KCS cause major problems for the ocular
surface, particularly the cornea, which relies upon tear proteins as
nutrients, anti-infectives and growth factors (Pﬂugfelder et al.,
2000). Treatment regimens are currently inadequate and are
focused on easing of symptoms rather than treatment of the
underlying disease (Fox, 2000).
The hallmark histopathological feature of SjS is the appearance
of focal, periductal and perivascular lymphocytic inﬁltrates in the
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to produce ﬂuid and protein. Effector CD4þ cells and regulatory
CD8þ T lymphocytes are the most common immune cells in these
inﬁltrates, with CD4þ cells being most prominent with a ratio of
4:1 compared to CD8þ cells in autoimmune-diseased glands. In
normal lacrimal glands, regulatory CD8þ cells aremore common, at
a ratio of 2:1, CD8 to CD4 (Segerberg-Konttinen, 1988; Zhu et al.,
2003b).
Gene therapy provides an opportunity for treating many
different diseases (Crystal, 1995; Lever and Goodfellow, 1995;
Goldﬁne et al., 1997), including autoimmune diseases (Zhu et al.,
2003b; Mathisen and Tuohy, 1998; Evans et al., 1998; Seroogy and
Fathman, 1998). Using a rabbit model of induced autoimmune
dacryoadenitis that mimics SjS (Zhu et al., 2003a), we previously
demonstrated in a prophylactic study that adenovirus-mediated
transduction of lacrimal gland acinar cells with either the
anti-inﬂammatory cytokine gene, viral interleukin-10 (vIL-10) or
the soluble tumor necrosis factor, (TNF)-a inhibitor, resulted in the
appearance of transgene products in tears combined with the
reduction of clinical and immunopathologic manifestations (Zhu
et al., 2003b). Later, in a therapeutic study using the same animal
model, we reported that the expression of an anti-inﬂammatory
cytokine gene in the lacrimal gland promoted recovery of tear
production and tear stability while reducing immunopathology in
rabbit lacrimal glands with induced autoimmune dacryoadenitis
(Trousdale et al., 2005). From these studies, it was concluded that
therapeutic levels of the anti-inﬂammatory gene product were
achieved in the lacrimal gland as well as on the corneal surface.
These results raised the question of whether the therapeutic
transgene product exits the transduced acinar cell via its apical or
basolateral membrane or both. The purpose of this study was to
determine the intracellular trafﬁcking and release pathway(s) of
transduced vIL-10.
The lacrimal gland acinar cell (LGAC) is a secretory epithelial cell
that comprises the major cell type within the lacrimal gland. These
cells are organized into acini, with adjacent apical membrane
domains surrounding a lumen (Scheme 1); ﬂuid and proteins
released at the apical plasma membrane drain from the lumenScheme 1. The diagram to the left depicts individual lacrimal acinar cells organized around
proteins from the cell. The apical plasma membrane domain can be distinguished in intact
the subapical actin ﬁlament network. The diagram to the right depicts a single acinar cell exp
beneath the actin-enriched apical plasma membrane. Some SV are undergoing fusion, by bei
where actin ﬁlaments have transiently disassembled beneath the apical plasma membra
arrows). rSV are also shown moving towards the apical plasma membrane to sustain the se
vesicular trafﬁc emerging from the trans-Golgi network can be sorted to the basolateral mthrough a series of ducts onto the ocular surface. Some apical
secretion of proteins into tear ﬂuid by the lacrimal gland occurs at
a constitutive level, while additional apical release of tear proteins
from secretory vesicles by fusion at the apical plasma membrane is
accelerated considerably by exposure to secretagogues. In situ
physiological stimulationoccurs in response to the releaseof agonists
from innervating sympathetic and parasympathetic neurons; the
actions of the physiological agonist, acetylcholine, are mimicked in
our in vitro study by the muscarinic agonist, carbachol (CCH).
Tear proteins destined for apical release from the lacrimal gland
are stored in the LGAC within a variety of secretory vesicles (SV),
which can be detected by electron microscopy as a heterogeneous
population of serous and mucous vesicles sized w0.5–1 mM (da
Costa et al., 2006; Jerdeva et al., 2005a; Marchelletta et al., 2008).
Some of the effectors that govern exocytosis of these SV at the apical
plasma membrane have been identiﬁed, while others remain to be
established (Wu et al., 2006). Brieﬂy, lacrimal gland SV are enriched
in speciﬁc proteins which provide targeting speciﬁcity, including
Rab proteins, small GTPases speciﬁc for donor membrane
compartments, and SNARE proteins which enable the formation of
a fusion pore between donor and acceptor membranes. In addition
to these effector proteins, additional factors contribute to SV
formation, maturation and exocytosis including cytoskeletal ﬁla-
ments (actin andmicrotubules) and their associatedmotor proteins.
Actin ﬁlaments and microtubules exist in all eukaryotic cells,
and have been implicated in diverse steps in vesicular transport.
Both polymers provide paths which support the transport of
membrane cargo driven by different types of motor proteins. The
ability of actin ﬁlaments to be rapidly remodeled in response to
cellular cues as well as to be utilized for generation of contractile
functions is also key in its activities in membrane trafﬁcking. Actin
ﬁlaments play an important role in the terminal exocytosis of SV
located beneath the apical plasma membrane in LGAC. Speciﬁcally,
disassembly of the subapical actin network occurs in stimulated
acini, facilitating access of the activated SV to the apical plasma
membrane. Coincident with this disassembly, a network of
basketlike actin ﬁlaments assembles around the base of the fusing
SV, facilitating compound fusion prior to the contact of thea central lumenal region, as well as the directions for apical and basolateral secretion of
tissue and in the in vitro reconstituted cultures by the intense labeling associated with
anded from the panel to the left. SV are shown concentrated in the subapical cytoplasm
ng enveloped in actin coats enriched in non-muscle Myo2 and Myo5c, adjacent to spots
ne. Exocytosis using these mechanisms is elicited by secretagogue stimulation (bold
cretory response, a response evoked by secretagogue stimulation (bold arrows). Other
embrane for constitutive exocytosis (dashed arrows).
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also participates in movement of the fusion intermediate towards
the apical plasma membrane, which is now more accessible due to
the local actin disassembly (Jerdeva et al., 2005a,b; Wu et al., 2006).
The contraction of actin ﬁlaments in retraction of the actin-coated
fusion intermediate to the apical plasma membrane is known to
utilize non-muscle myosin 2 (Myo2) (Jerdeva et al., 2005a). Another
actin-based motor protein, the unconventional myosin motor,
myosin 5c (Myo5c), is also enriched on SV and is an established SV
marker (Marchelletta et al., 2008). We have recently shown that
Myo5c also participates in aspects of actin coat formation, SV
compound fusion and content extrusion (Marchelletta et al., 2008).
Generally, microtubule-based vesicular transport occurs over
relatively long distances in cytoplasm. Our work in LGAC has
implicated microtubules and the microtubule-based motor, cyto-
plasmic dynein, in the formation and movement of a population of
recruitable secretory vesicles (rSV) from the cell interior towards
the apical membrane, to sustain the secretory response after the
initial burst of release from SV already localized in the subapical
cytoplasm (Wang et al., 2003). A schematic of the key processes
involved in movement and release of apically-targeted SV and the
roles of microtubules and actin ﬁlaments is shown in Scheme 1.
Exocytosis of vesicles can also occur at the basolateral
membrane of LGAC, although the molecular mechanisms are not
well established. However, functional studies do not suggest the
same dependence on cytoskeletal ﬁlaments as at the apical
membrane in secretory epithelia. Additionally, there is little
evidence for the existence of a pool of pre-formed vesicles which
serve as a source of secretory proteins that are released immedi-
ately upon cell stimulation, leading to the burst phenomenon as
seen for apically-released secretory products.
To begin to elucidate the mechanisms of transduced vIL-10
sorting and release from LGAC, we have examined its localization
within cultured LGAC, its release kinetics in response to CCH stim-
ulation, and the sensitivityof release toagentswhich inﬂuenceactin-
andmyosin-dependent secretory processes. Our results suggest that
themajority of vIL-10 is routed through the apical secretory pathway
where it is sequestered in a subpopulation of SV and released in
a process that involves actin ﬁlaments and myosin motors.
2. Methods
2.1. Reagents
Carbachol (CCH), rhodamine-phalloidin and goat anti-rabbit
secondary antibody conjugated to FITC were purchased from
Sigma–Aldrich (St. Louis, MO). Rat monoclonal antibody to IL-10
and BD OptEIA human IL-10 ELISA kit II were purchased from BD
Biosciences Pharmingen (San Diego, CA). Goat polyclonal antibody
to early endosomal antigen 1 (EEA1) and FITC-conjugated chicken
anti-rat IgG were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Mouse monoclonal antibody to g-adaptin was purchased
from Transduction Laboratories (Lexington, KY). Rabbit polyclonal
antibody to Myo5c was raised against a His-tagged protein fused to
human Myo5c tail as described previously (Rodriguez and Cheney,
2002). Latrunculin B (LAT) and the myosin light chain kinase
inhibitor, ML-7 [1-(5-Iodonaphthalene-1-sulfonyl)homopiper-
azine, HCl], were purchased from EMD Biosciences (San Diego, CA).
Matrigel was obtained from Collaborative Biochemicals (Bedford,
MA). ProLong antifade mounting media, Alexa Fluor 568-conju-
gated goat anti-rat IgG, Alexa Fluor 488 donkey anti-goat IgG,
Alexa Fluor 488 goat anti-mouse IgG1 (g1), Alexa Fluor 680 goat
anti-rat IgG, Alexa Fluor 647 phalloidin and 40, 6-diamidino-2-
phenylindole (DAPI) were from Molecular Probes/Invitrogen
(Eugene, OR). Paraformaldehyde was purchased from Polysciences
(Warrington, PA). Cell culture reagents were obtained from Life-Technologies. All other chemicals were reagent grade and obtained
from standard suppliers.
2.2. Cell isolation and culture
All animal work was performed in accordance with the Guiding
Principles for Use of Animals in Research. Female New Zealand
white rabbits weighing between 1.8 and 2.2 kg were obtained from
Irish Farms (Norco, CA). LGACs were isolated and maintained in
a laminin-based primary culture system for 2–3 days as described
previously (Gierow et al., 1995; Hamm-Alvarez et al., 1997; da Costa
et al., 1998). These culture conditions resulted in reconstitution of
epithelial polarity, establishment of acinar lumena, and formation
of SV (Scheme 1) (Gierow et al., 1995; Hamm-Alvarez et al., 1997; da
Costa et al., 1998, 2003; Wang et al., 2003; Xie et al., 2004a,b, 2006;
Jerdeva et al., 2005a,b).
2.3. Generation of adenoviral vectors
Replication-defective adenovirus serotype 5 (Ad) containing the
Epstein Barr virus IL-10 gene (AdvIL-10) and the green ﬂuorescent
protein (GFP) reporter gene (Ad-GFP) were constructed as
described previously (Zhu et al., 2002; Wang et al., 2004; Jerdeva
et al., 2005a). Replication-defective Ad5 containing the GFP-fused
tail region (amino acid residues 902–1742) of Myo5c (Ad-Myo5c-
tail-GFP) was constructed using the AdenoX expression kit 1
(Clontech) as described previously (Marchelletta et al., 2008).
2.4. Confocal ﬂuorescence microscopy
Rabbit primary LGACs were seeded ontoMatrigel-coated 18mm
circular glass coverslips in 12-well plates at 2  106 cells/well. On
day 2 of culture, reconstituted acini were transduced with AdvIL-10
at a MOI of 5 for 24 h. Cells were rinsed with Dulbecco’s phosphate
buffered saline (DPBS), then ﬁxed with 4% paraformaldehyde and
permeabilized with 0.1% Triton X-100 as previously described (da
Costa et al., 1998, 2003; Zhang et al., 2000; Wang et al., 2003; Jer-
deva et al., 2005b) and the distribution of vIL-10 and that of other
compartment markers was assessed by confocal ﬂuorescence
microscopy using a rat anti-human IL-10 monoclonal antibody and
other primary and secondary ﬂuorophore-conjugated antibodies or
ﬂuorescent probes. Confocal images were obtained with a Zeiss
LSM 510 Meta NLO imaging system equipped with Argon, red HeNe
and green HeNe lasers and a Coherent Chameleon Ti-sapphire
tunable multiphoton laser mounted on a vibration-free table.
Panels were compiled in Adobe Photoshop 7.0 (Adobe Systems Inc.,
Mountain View, CA).
In some experiments, Ad IL-10 (1  108 PFU in 0.2 mL) was
injected into each rabbit’s inferior lacrimal gland using a 25-gauge
butterﬂy needle on a tuberculin syringe. To avoid tissue damage
caused by rapid volume expansion, the microvolume delivery
system was set to deliver 10 mL at 10 s intervals (10 mL  20
repetitions ¼ 200 mL). Rabbits were sacriﬁced by injection of
pentobarbital sodium (56 mg/kg) 5 days after inoculation. The
inferior lacrimal glands of the injected eyes were removed from
each animal and dissected longitudinally into two parts and each
part was embedded in optimal cutting temperature (OCT)
compound (Miles, Inc., Elkhart, IN) after ﬁxing in 4% para-
formaldehyde and sucrose rehydration. Cryosections were used
and immunohistologic staining was performed as previously
described (Zhu et al., 2004; da Costa et al., 2006).
2.5. Secretion assays
Secretion assays were based on those described previously (da
Costa et al., 1998; Zhang et al., 2000; Wang et al., 2003). Rabbit
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1  106 cells/well. On day 2 of culture, reconstituted acini were
transduced with AdvIL-10 at a MOI of 5 for 24 h. Control and
transduced acini were then incubated in fresh medium for 1 h to
allow cell equilibration. In some cases, cells were treated with LAT
(10 mM, 60 min) or ML-7 (40 mM, 15 min). After treatment with or
without CCH (1–1000 mM, 0–180 min), aliquots of the medium
were removed for measurement of vIL-10 content or b-hexosa-
minidase activity. The amounts of vIL-10 or b-hexosaminidase
present under each condition were calculated from three replicate
wells/treatment in each assay, and values normalized to total
cellular protein before comparison across treatments using Stu-
dent’s t-test with the criterion for signiﬁcance at p  0.05 as
previously described (Hamm-Alvarez et al., 2003; Wang et al.,
2004). It should be noted that the lumenal regions in the recon-
stituted cultures are accessible to culture medium (Jerdeva et al.,
2005b), so that apically-released proteins can be measured in the
medium. In these cultures, we are unfortunately unable to distin-
guish between apical and basolateral release of proteins in unsti-
mulated LGAC, but the large bolus due to CCH stimulation is due to
apical exocytosis.
For measurement of vIL-10 release, aliquots of medium were
diluted and vIL-10 concentrations were quantiﬁed on 96-well
plates using BD OptEIA human IL-10 ELISA kit II (BD Biosciences
Pharmingen, San Diego, CA). The procedures were performed
according to the manufacturer’s recommended protocol and
concentrations determined from the standard curve. b-Hexosa-
minidase activity was assessed on 96-well plates using methyl-
umbelliferyl-D-glucosaminide as substrate. Protein contents were
determined on 96-well plates using the Micro BCA Protein Assay
(Pierce) with bovine serum albumin as standard. A Tecan GENios
Plus UV/Visible/ﬂuorescence plate reader (Phenix Research Prod-
ucts, Hayward, CA, USA) was used to measure reaction products. In
some experiments, LGACs transduced with Ad-Myo5c-tail-GFP or
Ad-GFP in addition to AdvIL-10 were processed as above to
measure release of vIL-10.3. Results
3.1. vIL-10 immunoreactivity is detected in large intracellular
vesicles in transduced LGAC
To determine the intracellular trafﬁcking and release pathways
of vIL-10, we ﬁrst assessed the intracellular distribution of vIL-10
transgene product in reconstituted LGAC transduced with AdvIL-10
by confocal ﬂuorescence microscopy. As shown in Fig. 1, under our
culture conditions individual acinar cells reassociate to formFig. 1. vIL-10 immunoreactivity is detected in large intracellular vesicles in transduced
LGAC. A. Rabbit LGACs were seeded onto Matrigel-coated 18 mm circular glass
coverslips in 12-well plates at 2  106 cells/well. On day 2 of culture, reconstituted
acini were transduced with AdvIL-10 at a MOI of 5 for 24 h. Cells were then ﬁxed and
processed to ﬂuorescently label vIL-10 (green), actin ﬁlaments (red) and cellular nuclei
(blue). The DIC image is also shown for comparison. Arrows, accumulation of vIL-10 in
large vesicles beneath the actin-enriched apical plasma membrane; arrowhead,
accumulation of vIL-10 in basolateral structures; bar, 10 mm and *, apical/lumenal
region. A schematic diagram of the acini transduced with AdvIL-10 is also shown for
reference. The lumen (indicated with an asterisk) is bounded by the apical plasma
membranes (thick lines). Basolateral plasma membranes are illustrated as thinner
lines. B. Immunocytochemistry studies of IL-10 expression at 5 days post-injection in
rabbit inferior lacrimal glands. AdvIL-10 (1  108 PFU in 0.2 mL) was injected into each
rabbit’s inferior lacrimal gland as described in Section 2. 5 days after inoculation,
rabbits were sacriﬁced and inferior lacrimal glands were removed from each animal.
After ﬁxing in 4% paraformaldehyde and sucrose rehydration, the glands were
embedded in OCT and frozen sections were processed to ﬂuorescently label vIL-10
(green), actin ﬁlaments (red) and cellular nuclei (blue). The DIC image is also shown for
comparison. Arrows, accumulation of vIL-10 in vesicle-like structures beneath the
apical plasma membrane; bar, 10 mm and *, apical/lumenal region.
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domain that can be identiﬁed by the intense labeling due to the
subapical actin ﬁlament network (da Costa et al., 1998). The nuclei
are localized towards the basolateral membranes. vIL-10 immu-
noreactivity was detected within apparent vesicles in resting acini
transduced with AdvIL-10; it accumulated primarily in large (0.5–
1 mm) vesicles as estimated using the Ruler Tool within the Zeiss
LSM software. This labeling was largely detected just beneath the
lumenal regions. Some intracellular labeling associated with vIL-10
could also be detected adjacent to the basolateral plasma
membrane (Fig. 1A). No immunoﬂuorescent signal could be
recovered in control (nontransduced) cells (data not shown).
To show that the intracellular distribution of vIL-10 transgene
product we observed in the transduced primary LGAC culture
system used, was comparable to that detected in intact tissue, we
used AdvIL-10 to inject intact rabbit lacrimal gland and examined
the distribution of vIL-10 transgene product in transduced lacrimal
gland tissue. As shown in Fig. 1B, consistent with the in vitro result,
vIL-10 immunoreactivity was detected in vesicle-like structures
beneath the apical plasmamembranes in transduced lacrimal gland
tissue.
In this and subsequent experiments, it should be noted that our
confocal ﬂuorescence microscopy analysis detected strong vIL-10
immunoﬂuorescence in about 20–30% of cells, suggesting a lower
transduction efﬁciency with this vector than with other Ad5-
derived vectors reported previously in LGAC (Wang et al., 2003,
2004; Jerdeva et al., 2005a,b).Fig. 2. vIL-10 is partially co-localized with biosynthetic but not basolateral endosomal mark
for Fig. 1A. Cells were then ﬁxed and processed to ﬂuorescently label vIL-10 (green), g-adapti
of vIL-10 and g-adaptin; bar, 10 mm and *, apical/lumenal region.3.2. vIL-10 is partially co-localized with biosynthetic but not
endosomal markers
We examined the extent of co-localization of vIL-10 with
biosynthetic membranes’ compartments (i.e. the Golgi complex
and trans-Golgi network) which are responsible for producing and
packaging vesicles containing secretory proteins that are targeted
either to the apical or basolateral plasma membranes. As expected,
in resting cells transduced with AdvIL-10, vIL-10 was partially co-
localized with the trans-Golgi network marker, g-adaptin (Fig. 2A).
A lesser degree of co-localization was observed with the Golgi
marker, Rab6 (data not shown).
Since biosynthetic compartments communicate with apically
and basolaterally-targeted exocytotic pathways, and basolateral
release to the interstitium of the lacrimal gland was one potential
route of secretory protein release, we examined the co-localization
of vIL-10 with membrane trafﬁcking proteins associated with
basolateral endosomes which accommodate the transit of some
basolaterally-targeted secretory products. As shown in Fig. 2B, in
resting cells transducedwith AdvIL-10, therewas no co-localization
of vIL-10 with the early endosome marker, EEA1. There was also no
co-localization of vIL-10 with the recycling endosome marker,
Rab4, or the early endosomemarker Rab5a (data not shown). These
ﬁndings suggest that vIL-10 is not extensively enriched in traf-
ﬁcking pathways in communication with the basolateral
membranes, although they do not exclude the possibility that some
vIL-10-enriched vesicles may be able to transit directly from Golgiers. Rabbit LGACs were cultured and transduced with AdvIL-10 as described in legend
n (A) or EEA1 (B) (red), actin ﬁlaments (purple) and DAPI (blue). Arrows, co-localization
J. Xie et al. / Experimental Eye Research 88 (2009) 467–478472and trans-Golgi sorting compartments and fuse at the basolateral
membranes.
We had difﬁculty assessing the co-localization of vIL-10 with
markers of mature apically-targeted SV, since the ﬁxation condi-
tions that resulted in optimal resolution of these markers (Rab3D
and Myo5c) were not compatible with the ﬁxation conditions that
yielded strong vIL-10 immunoﬂuorescence. The possibility that vIL-
10 was packaged in apically-targeted SV, consistent with its
observed enrichment in large vesicles adjacent to the actin-
enriched lumena (Fig. 1), was subsequently explored from a func-
tional standpoint as well as using co-transduction with an SV
marker, Myo5c for confocal ﬂuorescence microscopy.3.3. vIL-10 release from LGAC is increased by CCH stimulation
To determine how vIL-10 secretion from LGAC responded to
secretagogue stimulation, basal and carbachol (CCH)-stimulated
release of vIL-10 was measured from LGAC using ELISA andFig. 3. Dose dependence of CCH-stimulated release of vIL-10 and b-hexosaminidase
from LGAC. Rabbit LGACs were seeded onto Matrigel-coated 24-well plates at
1 106 cells/well. On day 2 of culture, reconstituted acini were transduced with AdvIL-
10 at a MOI of 5 for 24 h. Control and transduced acini were then incubated in fresh
medium for 1 h to allow cell equilibration. After treatment without or with 1, 10, 100
and 1000 mM CCH for 30 min, aliquots of the mediumwere collected and processed for
measurement of vIL-10 (A) and b-hexosaminidase (B) release using ELISA and
biochemical assays, respectively. vIL-10 and b-hexosaminidase release are plotted as %
of total, with total deﬁned as the maximal release elicited by 100 mM CCH at 30 min in
acini transduced with AdvIL-10. n ¼ 4. Error bars represent s.e.m.biochemical assays, respectively. The secretory product, b-hexosa-
minidase (da Costa et al., 1998; Andersson et al., 2006) was
measured under the same conditions, for comparison. In order to
determine the optimal dose for further studies on stimulated
secretion, release of vIL-10 and b-hexosaminidase from LGAC was
measured following exposure to 1 mM,10 mM,100 mM or 1 mM CCH
for 30 min time interval. The dose dependence of CCH-stimulated
release of vIL-10 and b-hexosaminidase is shown in Fig. 3. These
experiments showed that transduced LGAC secreted vIL-10 at a low
but detectable rate in the absence of CCH. CCH stimulation
increased the secretion of both vIL-10 and b-hexosaminidase,Fig. 4. Time course of CCH-stimulated release of vIL-10 and b-hexosaminidase from
LGAC. Rabbit LGACs were cultured and transduced with AdvIL-10 as described in the
legend for Fig. 3. After treatment with or without 100 mM CCH at time intervals from
0 to 180 min, aliquots of the mediumwere collected and processed for measurement of
vIL-10 (A) and b-hexosaminidase (B) release using ELISA and biochemical assays,
respectively. vIL-10 and b-hexosaminidase release are plotted as % of total, with total
deﬁned as the maximal release elicited by 100 mM CCH at 180 min. n ¼ 3 and *,
signiﬁcant at p  0.05, AdvIL-10 (þ)CCH versus AdvIL-10 ()CCH. Error bars represent
s.e.m.
Fig. 5. Acute release of vIL-10 and b-hexosaminidase from LGAC. Rabbit LGACs were
cultured and transduced with AdvIL-10 as described in the legend for Fig. 3. After
treatment with or without 100 mM CCH at time intervals from 0 to 30 min, aliquots of
the medium were collected and processed for measurement of vIL-10 (A) and b-
hexosaminidase (B) release using ELISA and biochemical assays, respectively. vIL-10
and b-hexosaminidase release are plotted as % of total, with total deﬁned as the
maximal release elicited by 100 mM CCH at 30 min. n ¼ 5 and *, signiﬁcant at p  0.05,
AdvIL-10 (þ)CCH versus AdvIL-10 ()CCH (A) and AdvIL-10 (þ)CCH versus Control
(þ)CCH (B). Error bars represent s.e.m.
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1 mM. The similar dose response of vIL-10 and b-hexosaminidase
suggested that both cargo proteins were secreted largely by similar
mechanisms. This observation is consistent with other measure-
ments of the optimal CCH dose required for maximal stimulation in
lacrimal acini (Gierow et al., 1995; da Costa et al., 2003).
We therefore chose to use the maximal CCH concentration
(100 mM) to perform time course study of CCH-stimulated release
of vIL-10 and b-hexosaminidase at time intervals from 0 to 180min.
As shown in Fig. 4, CCH stimulation signiﬁcantly (p  0.05)
increased the secretory rate at all times measured (0–180 min). The
curve appeared biphasic, with a robust and linear increase from 0 to
90 min, and a tapering response from 90 to 180 min. The sensitivity
of the release to CCH and the rapid burst of release at early times
(50% of the total product released was released within the ﬁrst
30 min of the 180 min incubation period) suggested that
a substantial portion of vIL-10 transgene product was directed into
the acinar cells’ regulated apical secretory pathway. This observa-
tion is also consistent with studies which previously have recov-
ered vIL-10 in tears from the lacrimal glands of rabbits transduced
with AdvIL-10 (Zhu et al., 2004).
3.4. Acute release of vIL-10 from LGAC
To further characterize the kinetics of vIL-10 release, the acute
vIL-10 release proﬁle was assessed. The time course of release of
vIL-10 and b-hexosaminidase from control and transduced acini
over 30 min without or with 100 mM CCH is summarized in Fig. 5.
Fig. 5A shows the effect of 100 mM CCH on vIL-10 release; little vIL-
10 was released within the ﬁrst 5 min, but the onset of a rapid
release at 10 min was detected that was essentially complete by
15 min. Little additional release occurred between 15 and 30 min.
Fig. 5B shows the time course of release of b-hexosaminidase in
parallel. b-Hexosaminidase shows an initial rapid phase of release
(0–15 min), and a second ﬂat phase of release (15–30 min). This
latter proﬁle is consistent with the rapid discharge of pre-formed
SV followed by the sustained release from rSV, as suggested
previously (Wang et al., 2003). These acute secretion experiments
showed that the kinetics of release of vIL-10 are similar but not
identical to that of secretory protein, b-hexosaminidase. Speciﬁ-
cally, the burst of release characteristic of proteins in pre-formed SV
is delayed slightly for vIL-10, suggesting that the bulk of this protein
is in a CCH-sensitive pool of vesicles that can be rapidly but not
immediately mobilized.
3.5. Disruption of actin ﬁlaments alters vIL-10 secretion from LGAC
We have previously shown that disassembly of actin microﬁla-
ments with latrunculin B (LAT) enhanced the CCH-stimulated
release of bulk protein and the transduced SV marker, syncollin-
GFP (Jerdeva et al., 2005a), likely due to removal of the actin ﬁla-
ment network that normally prevents access of SV to the apical
plasma membrane (Scheme 1). We have postulated that this
response is due to the increased access of SV to the apical plasma
membrane, once the dense subapical ﬁlament network is removed.
To investigate the possible involvement of actin ﬁlaments in vIL-10
secretion, we examined the effect of LAT on CCH-stimulated release
of vIL-10 from control and transduced acini. For simplicity, we
focused on 0 min, 30 min and 180 min time points. As shown in
Fig. 6A, secretion experiments indicated that disassembly of actin
ﬁlaments with LAT resulted in a small but signiﬁcant enhancement
of CCH-stimulated vIL-10 secretion at 30 min, a phenomenon very
similar to the stimulatory effect of LATon CCH-stimulated secretion
of the speciﬁc SV marker, syncollin-GFP (Jerdeva et al., 2005a).
These data were further supported by confocal ﬂuorescence
microscopy. Consistent with the biochemical studies shown earlier(Figs. 3–5), acute CCH stimulation for 30 min reduced intracellular
vIL-10 staining in untreated acini, especially the immunoﬂuores-
cence signal adjacent to the apical plasma membrane (Fig. 6B).
Confocal ﬂuorescence microscopy also revealed that LAT pretreat-
ment appeared to reduce intracellular vIL-10 staining in transduced
cells stimulated with 100 mM CCH for 30 min, although it was not
clear if the effect was more pronounced at the apical plasma
membrane due to the extensive disruption of actin ﬁlament-asso-
ciated structures caused by LAT (Fig. 6B). These results suggest that
Fig. 6. Disruption of actin ﬁlaments modulates vIL-10 secretion from LGAC. A. Effect of latrunculin B (LAT) pretreatment on CCH-stimulated release of vIL-10 from LGAC. Rabbit
LGACs were cultured and transduced with AdvIL-10 as described in legend for Fig. 3. Cells were then pretreated with LAT (10 mM) for 60 min before being treated without or with
100 mM CCH at time intervals from 0 to 180 min. Aliquots of the mediumwere collected and processed for measurement of vIL-10 release using ELISA assays. vIL-10 release is plotted
as % of total, with total deﬁned as the maximal release elicited by 100 mM CCH at 180 min in untreated cells. n ¼ 5 and *, signiﬁcant at p  0.05, LAT AdvIL-10 (þ)CCH versus AdvIL-10
(þ)CCH. Error bars represent s.e.m. B. Effect of LAT pretreatment on vIL-10 distribution in LGAC. Rabbit LGACs were cultured and transduced with AdvIL-10 as described in legend for
Fig. 1A. Cells were then pretreated with LAT (10 mM) for 60 min before being treated without or with 100 mM CCH for 30 min. Cells were ﬁxed and processed to ﬂuorescently label
vIL-10 (green), actin ﬁlaments (red) and cellular nuclei (blue). Arrows, subapical accumulation of vIL-10; bar, 10 mm and *, apical/lumenal region.
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secretory pathway at the apical plasma membrane.
We have previously shown that the microtubule array and
cytoplasmic dynein participate in apically-targeted transport of rSV
(Wang et al., 2003), a response which aids in maintaining the
secretory response following the immediate release of pre-formed
SV. Parallel experiments using the microtubule-disrupting agent,
nocodazole, revealed no evidence for a role for microtubules in
CCH-stimulated release of vIL-10 (data not shown). These results
suggest that the microtubule cytoskeleton does not play a critical
role in acute vIL-10 secretion from LGAC.
3.6. Inhibition of myosin motors signiﬁcantly reduces
vIL-10 secretion
ML-7 has been utilized extensively as a selective inhibitor of
myosin light chain kinase (Saitoh et al., 1987), leading to speciﬁc
inhibition of non-muscle Myo2 activity. Our previous work has
established that ML-7 treatment results in stabilization of actin-
coated fusion intermediates in CCH-stimulated acini (Jerdeva et al.,
2005a), likely due to impaired ability of Myo2 associated with the
actin coat surrounding the fusing vesicles to exert force to promote
SV compression and fusion. To test whether CCH-stimulated vIL-10
release was sensitive to ML-7, we pretreated LGAC with ML-7 prior
to measurement of vIL-10 release without and with CCH. As shown
in Fig. 7, ML-7 signiﬁcantly reduced CCH-stimulated release of vIL-
10 at both 30 min and 180 min, suggestive of a role for non-muscle
Myo2 in its exocytosis. This effect was comparable to our previous
observation that the CCH-stimulated release of the exogenous
secretory product, syncollin-GFP, was also signiﬁcantly reduced by
ML-7 (Jerdeva et al., 2005a).
Myo5c is an unconventional myosin motor protein that is highly
expressed in secretory epithelial cells from pancreas and lacrimal
gland (Rodriguez and Cheney, 2002; Chen et al., 2006; MarchellettaFig. 7. Myosin motors participate in vIL-10 secretion from LGAC. Rabbit LGACs were
cultured and transduced with AdvIL-10 as described in legend for Fig. 3. Cells were
then pretreated with the non-muscle Myo2 inhibitor, ML-7 (40 mM), for 15 min before
being treated without or with 100 mM CCH at time intervals from 0 to 180 min.
Aliquots of the medium were collected and processed for measurement of vIL-10
release using ELISA. vIL-10 release is plotted as % of total, with total deﬁned as the
maximal release elicited by 100 mM CCH at 180 min in untreated acini. n ¼ 8 and *,
signiﬁcant at p  0.05, ML-7 AdvIL-10 (þ)CCH versus AdvIL-10 (þ)CCH. Error bars
represent s.e.m.et al., 2008). This protein is enriched in the subapical cytoplasm of
lacrimal acini, in association with SV (Fig. 8B) (Marchelletta et al.,
2008). Our previous work has shown extensive co-localization of
Myo5c with the SV marker, rab3D. We have also shown that
disruption of Myo5c activity through Ad-mediated expression of
a dominant negativeMyo5c-tail-GFP construct results in disruption
of actin coat function during SV exocytosis and results in functional
inhibition of exocytosis (Marchelletta et al., 2008). To test if Myo5c
was functionally important in vIL-10 release, we used the dominant
negative Myo5c-tail domain labeled with GFP inserted into an Ad
expression vector (Ad-Myo5c-tail-GFP) to transduced LGAC. This
construct functionally inhibits Myo5c activity, since the tail
competes for cargo binding but the dominant negative construct is
missing the head or motor domain and is therefore unable to
transport the bound cargo along actin ﬁlaments (Rodriguez and
Cheney, 2002). Ad-GFP was used as a control for Ad-Myo5c-tail-
GFP in the dual transduction experiments. Either construct was co-
transduced with AdvIL-10 into LGAC. The transduction efﬁciencies
of the Ad-Myo5c-tail-GFP and Ad-GFP constructs in LGAC, with or
without AdvIL-10, were >80%, so essentially all vIL-10 expressing
LGACs were co-transduced. As shown in Fig. 8A, co-transduction
with Ad-Myo5c-tail-GFP signiﬁcantly (p  0.05) and substantially
decreased CCH-stimulated vIL-10 secretion at 30 min and 180 min
relative to cells doubly-transduced with AdvIL-10 and Ad-GFP.
Moreover, confocal ﬂuorescence microscopy revealed that Ad-
Myo5c-tail-GFP enhanced intracellular vIL-10 staining in AdvIL-10/
Ad-Myo5c-tail-GFP-transduced cells stimulated by 100 mM CCH for
30 min compared to cells doubly-transduced with AdvIL-10 and
Ad-GFP (Fig. 8C). Unlike the diffuse cytoplasmic GFP labeling from
Ad-GFP transduction, Myo5c-tail-GFP was enriched largely in
subapical compartments in LGAC. Considerable co-localization of
vIL-10 and Myo5c-tail-GFP was also observed in the subapical
region of resting acini doubly-transduced with AdvIL-10 and Ad-
Myo5c-tail-GFP, while signiﬁcantly more vIL-10 immunoreactivity
was recovered in Myo5c-tail-GFP-positive subapical vesicular
structures in doubly-transduced cells stimulated by 100 mMCCH for
30 min (Fig. 8C). These effects support a largely apical release
mechanism for vIL-10 from LGAC which utilizes, at least in part,
actin ﬁlaments, non-muscle Myo2 and Myo5c in ways previously
implicated in SV exocytosis of other proteins.
4. Discussion
In this study, we have analyzed the intracellular trafﬁcking and
route of release of a therapeutic protein, vIL-10, introduced into
LGAC using an adenoviral vector. Analysis of the intracellular
routing and disposition of therapeutic proteins introduced by gene
therapy is a critical element in evaluating their ultimate potential
and efﬁcacy. For instance, if a protein destined for secretion is
introduced into the target cell but is not appropriately targeted to
SV, this proteinwill not ultimately reach its target site. The problem
becomes more complex when dealing with epithelial cells, which
maintain distinct plasma membrane domains, apical and baso-
lateral, facing different exteriors, in this case the ocular surface/tear
ﬁlm and the interstitium, respectively. Our study has demonstrated
that vIL-10 immunoreactivity is associated with large apparent SV,
indicating that it is appropriately packaged into membrane-boun-
ded organelles. Analysis of the size of the vesicles, their intracel-
lular locale and their co-localization with other markers of
biosynthetic compartments suggests that vIL-10 is sorted primarily
into apically-targeted SV. Observation that exposure of transduced
LGAC to CCH elicited a burst of release of vIL-10 substantiates our
hypothesis that these organelles are SV.
Our previous studies have demonstrated a dual role for actin
ﬁlaments in exocytosis of SV (Jerdeva et al., 2005a). CCH stimula-
tion is associated with the rapid and transient formation of actin
Fig. 8. Myosin 5c participates in vIL-10 secretion from LGAC. A. Effect of Ad-Myo5c-tail-GFP transduction on CCH-stimulated release of vIL-10 from LGAC. Rabbit LGACs were seeded
onto Matrigel-coated 24-well plates at 1  106 cells/well. On day 2 of culture, reconstituted acini were singly or doubly-transduced with Ad-GFP, Ad-Myo5c-tail-GFP or AdvIL-10 at
a MOI of 5 for 24 h. Control and transduced acini were then incubated in fresh medium for 1 h to allow cell equilibration. After treatment with or without 100 mM CCH at time
intervals from 0 to 180 min, aliquots of the medium were collected and processed for measurement of vIL-10 release using ELISA assays. vIL-10 release is plotted as % of total, with
total deﬁned as the maximal release elicited by 100 mM CCH at 180 min in acini doubly-transduced with AdvIL-10 and Ad-GFP. n ¼ 10 and *, signiﬁcant at p  0.05, Ad-Myo5c-tail-
GFP AdvIL-10 (þ)CCH versus Ad-GFP AdvIL-10 (þ)CCH. Error bars represent s.e.m. B. Rabbit LGACs were seeded onto Matrigel-coated 18 mm circular glass coverslips in 12-well
plates at 2  106 cells/well. On day 3 of culture, reconstituted acini were ﬁxed and processed to ﬂuorescently label Myo5c (green) and actin ﬁlaments (red). The DIC image is shown
for comparison and the overlay image shows the super-imposition of the ﬂuorescence image and the DIC image. Arrows, large apparent SV enriched in Myo5c; bar, 5 mm and *,
apical/lumenal region. C. Effect of Ad-Myo5c-tail-GFP transduction on vIL-10 distribution in LGAC. Rabbit LGACs were seeded onto Matrigel-coated 12-well plates at 2  106 cells/
well. On day 2 of culture, reconstituted acini were singly or doubly-transduced with Ad-GFP, Ad-Myo5c-tail-GFP or AdvIL-10 at a MOI of 5 for 24 h. Cells were then ﬁxed and
processed to ﬂuorescently label vIL-10 (red), GFP (green), actin ﬁlaments (purple) and cellular nuclei (blue). Arrows, co-localization of vIL-10 and Myo5c-tail-GFP; bar, 10 mm and *,
apical/lumenal region.
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intermediates. Inhibition of Myo5c or non-muscle Myo2 prevents
the formation of actin-coated fusion intermediates or traps these
structures at an intermediate stage in the subapical cytoplasm,
while concomitantly reducing the amount of secretory proteins
recovered in the extracellular ﬂuid. By utilizing ﬂuorescence
recovery after photobleaching (FRAP) analysis, we have also shown
that in addition to the assembly of actin coats around fusing vesi-
cles that the actin network underlying the apical plasmamembrane
becomes much more dynamic (Jerdeva et al., 2005a). Disassembly
of this actin barrier enhances the basal and CCH-stimulated release
of SV proteins, suggesting a barrier role for this second population
of actin ﬁlaments in exocytosis (Scheme 1), distinct from the actin
coating on fusion intermediates. In the current study we have
shown that the CCH-stimulated vIL-10 secretion from LGAC
exhibits comparable sensitivity to LAT treatment relative to syn-
collin-GFP, an SV marker (Jerdeva et al., 2005a), suggesting that
secretion of vIL-10 is optimal when the actin barrier is transiently
removed. As well, relative to syncollin-GFP (Jerdeva et al., 2005a),
CCH-stimulated vIL-10 secretion from LGAC exhibits comparable
sensitivity to ML-7 treatment and dominant negative Myo5c
overexpression, suggesting that optimal secretion of vIL-10
requires the activity of both of these myosin motors. Finally, vIL-10
immunoﬂuorescence is co-localized with that fromMyo5c-tail-GFP
which has been previously shown to associate with SV (Marche-
lletta et al., 2008). Each of these responses is characteristic of the
behavior of other secretory or tear proteins in LGAC; therefore we
propose that most vIL-10 is routed through a speciﬁc SV population
at the apical plasma membrane.
Since the maintenance of prolonged secretory responses of
some secretory proteins are dependent upon the continued traf-
ﬁcking of materials along cellular microtubules to produce new SV,
it was somewhat surprising that we detected no inhibitory effects
of the microtubule-destabilizing agent, nocodazole, on CCH-stim-
ulated vIL-10 release. However, our explorations of the role of the
microtubule array in rSV maturation and exocytosis have focused
only on b-hexosaminidase and bulk protein. As is shown in Fig. 5,
the acute release kinetics of b-hexosaminidase differ from those of
vIL-10, suggesting that they may be packaged in distinct SV.
Interestingly, inhibition of Myo5c does not impair CCH-stimulated
b-hexosaminidase release, although it inhibits the CCH-stimulated
release of syncollin-GFP (Marchelletta et al., 2008). Ample evidence
exists for the existence of multiple SV types in LGAC, ranging from
the observation of vesicles that exhibit different electron densities
consistent with different contents (da Costa et al., 2006), to the
observation that different SV markers such as syncollin-GFP, b-
hexosaminidase and now vIL-10 exhibit subtly different acute
release kinetics. By extension, the pathways involved in the
production of different rSV in LGAC may not be equally dependent
upon the microtubule array.
In conclusion, here we have demonstrated that a transduced
protein can be delivered and released primarily through apical
exocytosis from SV in an actin- and myosin-dependent manner in
LGAC. This has important ramiﬁcations for our understanding of the
therapeutic mechanisms of action of transduced vIL-10 in the rabbit
model of autoimmune dacryoadenitis. This also suggests that the
LGAC can be engineered, not only for regulated release of thera-
peutic proteins for diseases of the lacrimal gland, but that it can be
targeted more broadly as a reservoir that can sustain the regulated
release of therapeutic proteins which, when released into tear ﬂuid,
can treat disorders of the cornea and even the posterior segment.
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